Scandion Oncology A/S (“Scandion Oncology”) today announces that the company has selected Radboud University Medical Centre in Nijmegen, the Netherlands, as collaborator for the Boost4Health internationalisation voucher. As previously announced this grant amounts to EUR 14,999. Scandion Oncology received additionally EUR 5,000 from the Boost4Healths program (Product Validation voucher). The scientific collaboration concerns the use of SCO-101 to revert resistance to anti-estrogen treatment in patients with advanced breast cancer.
The scientific collaboration with Radboud University Medical Centre in Nijmegen, the Netherlands, concerns the use of SCO-101 to revert resistance to anti-estrogen treatment in patients with advanced breast cancer. Anti-estrogens are frequently used to treat breast cancer patients but unfortunately, most of the patients will over time develop resistance to the treatment. Scandion Oncology has solid preclinical data demonstrating that SCO-101 can reverse anti-estrogen resistance in breast cancer. The Dutch collaborators are experts in molecular analyses of breast cancer and anti-estrogens and will within this collaborative project perform studies on the mechanisms of action of SCO-101 in reverting anti-estrogen resistance. The experimental studies will start early January 2019 and is expected to be finalized during June 2019. Scandion Oncology holds all commercial rights to these results.
CSO Jan Stenvang says “I am very excited and I see this collaboration as an extremely important step in Scandion Oncology’s efforts to perform clinical trials with SCO-101 in breast cancer patients with anti-estrogen resistant disease. Knowing that almost all breast cancer patients with metastatic estrogen receptor positive disease will develop resistance to anti-estrogen therapy, the potential patient benefit and thereby market share for SCO-101 treatment of future breast cancer patients could be very significant. Having identified the exact mechanisms of action of SCO-101 in reverting anti-estrogen resistance will allow Scandion Oncology to develop so called predictive biomarkers to be used to pre-select patients with the highest likelihood of responding to SCO-101. Clinical protocols for SCO-101 treatment in combination with anti-estrogens in anti-estrogen resistant breast cancer patients are now on our priority list. We thus see this collaboration as a very important strategic step for Scandion Oncology’s international clinical development plans.”
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08